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1. Introduction 
1.1 Incidence and mortality of pulmonary embolism 
Pulmonary embolism (PE) is not a disease by itself but may have a venous thrombotic 
source and is therefore more precise if classified as venous thromboembolism (VTE). 
According to the international registry, the frequency of VTE is 150-200 new cases 
diagnosed per 100,000 inhabitants per year. Out of this, one third is diagnosed as primary 
PE (Oger, 2000; Walther et al., 2009). Following the diagnosis the average mortality is 11% in 
the first two months (Goldhaber et al., 1999). In the ICOPER study, the total mortality of PE 
in the first 3 months was 17.5%. However, in the long run the recurrent embolic episodes 
and lack of revascularisation caused progressive pulmonary hypertension (Goldhaber et al., 
1999). The mortality of untreated PE is 30% and with adequate treatment can be reduced to 
2-8% (Goldhaber, 1998). The hospital mortality of haemodynamically stable PE patients is 
overall 10% in general, 4% in the first 24 hours (Kline et al., 2003). Mortality of PE with 
respiratory and cardiovascular failure on hospital admission can be up to 95%. Hospital 
mortality is 80% in patients requiring mechanical ventilation and 77% in those who need 
cardiopulmonary resuscitation in the first 24 hours (Janata et al., 2002). Only 29% of fatal PE 
cases (verified at hospital autopsies) were previously diagnosed clinically. Based on these 
facts, the primary goal in PE management is a rapid and clear diagnosis followed by the 
appropriate treatment (S. Büchner & Th. Hachenberg, 2005). 
1.2 Etiology 
The source of PE in majority of cases can be due to the postoperative state, trauma injury, 
long term immobilization causing deep vein thrombosis (DVT), or congenital/acquired 
coagulation defect (Goldhaber & Morrison, 2002; Schürmann et al., 1992; Spöhr et al., 2005; 
Tapson, 2008). There are congenitally predisposed and non-influenced factors in the 
aetiology of VTE. Most important ones are: old age, family predisposition, genetic defects – 
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activated protein C resistance (Dahlbäck, 1995), 20210A mutation of factor II (Poort et al., 
1996), hyperhomocysteinaemia (den Heijer et al., 1996), antithrombin III, protein C and 
protein S deficiency (Demers et al., 1992).     
Aetiology can be divided into two groups:  
a/ Congenital risk factors: Lack of anti-thrombin III (0.2%), lack of protein C (0.8%), lack of 
protein S (1.3%), Leiden point-mutation of factor V (3.0%), mutation of prothrombin G20210 
A (2.3%) (Ageno et al., 2006). 
b/ Acquired risk factors: DVT, phlebitis, immobilization, bed rest, post-traumatic and 
operative state, sepsis, diabetes, smoking, hypovolaemia, diuretic treatment, elevated 
plasma/blood viscosity, coagulation disorders (disseminated intravascular coagulation, 
heparin induced thrombocytopenia (HIT), drug induced coagulopathy (anticoncipient, 
oestrogen), obesity, sedentary lifestyle, pregnancy, postnatal state, cardiac insufficiency, 
heart valve disorders, artificial valves, central venous catheter, pacemaker electrode, 
tumour, old age, nephrosis syndrome (Goldhaber et al., 1997). 
1.3 Pathophysiology 
Based on the occlusion of the pulmonary vasculature we can differentiate between mild: 
25%, intermediate: 25-50% and severe: 50% PE types. The pathophysiology of PE runs on 
two parallel pathways: 
 haemodynamic alterations: The oxygen demand and workload on the right atrium 
increases with the afterload, while cardiac index decreases (even with normal arterial 
blood pressure and tachycardia) leading to systemic hypotension. The right intraatrial 
pressure increases and the pressure gradient between the right atrium and the aorta 
drops, pushing the intraventricular septa into the cavity of the left ventricle (LV) (D-
sign). A severe shock with global cardiac ischemia can develop. 
 hypoxaemia: Ventilation/perfusion (V/Q) disequilibrium rises. Areas with 
hypoperfusion have an increased V/Q, while it decreases on hypoventilated 
(atelectasis) or normally perfused regions. Low LV cardiac output results from shunt-
perfusion and hypoxaemia (Nowak et al., 2007). Platelet released vasoactive substances 
cause vaso- and bronchospasm in the affected regions (Stratmann & Gregory, 2003; 
Wood, 2002; Konstantinides, 2005). Surfactant production impairs in the early phase of 
pulmonary hypertension. Due to shunt-perfusion, global arterial hypoxaemia develops 
with a decrease of arterial oxygen saturation (Konstantinides & Hasenfuss, 2004). 
1.3.1 Risk stratification 
Based on the haemodynamic symptoms,PE can be either massive, characterised by systolic 
blood pressure lower than 90 mmHg or a systolic blood pressure decrease > 40 mmHg, or 
non-massive which includes submassive severity characterised by increased right ventricular 
pressure (Torbicki et al., 2000). 
The most recent PE guideline changed the definitions of various risk groups, according: 
high risk and non-high risk categories.  
High risk definition: Shock and/or hypotension (systolic blood pressure <90 mmHg or a drop 
in blood pressure greater than 40 mmHg within 15 min. excluding other causes of shock 
(e.g. arrhythmia, hypovolaemia, sepsis etc.).  
All others can be listed under non-high risk PE. Based on right ventricular (RV) pressure 
overload and myocardial injury, we can differentiate a subgroup, the intermediate risk PE 
patients without shock.  
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Table 1. Risk stratification according to the ESC 2008 guidelines. 
The prognosis of the increased RV pressure (intermediate risk) group is worse than the 
normal RV pressure group (Torbicki et al., 2008).  
 
The clinical probability of pulmonary embolism in outpatients
(Wells et al., 2001) 
Score 
  
Clinical signs  
Deep vein thrombosis (DVT) +3.0 
Pulmonary embolism (PE) suspected from other signs or symptoms +3.0 
Hearth rate >100 / min +1.5 
Operation, immobilization, bed rest in the last 4 weeks +1.5 
Former DVT or PE +1.5 
Hemoptysis +1.0 
Malignancy (active or confirmed in the last 6 months) +1.0 
  
Probability of PE   
Small < 2.0 
Medium 2.0-6.0 
High > 6.0 
Table 2. Clinical probability score 
1.4 Pulmonary embolism diagnostic strategy 
Acute PE, in the presence of shock/hypotension, RV dysfunction and myocardial injury 
causes high mortality risk. Rapid and clear diagnosis and appropriate therapy may help to 
improve survival of this critical condition.  
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1.4.1 Physical signs of PE 
In the presence of typical physical signs (dyspnoea, chest pain, syncope, tachypnea, 
tachycardia, cough, hemoptysis, signs of DVT, cyanosis, etc.) the diagnosis of PE is 90% 
reliable, although the severity of symptoms do not correlate with the actual illness. About 
10% of high-risk cases are recognised by radiology imaging and considered to be non-high 
risk according to physical symptoms. 
Physical signs and symptoms: severe stabbing chest pain (52%), tachycardia (26%), cough 
(20%), cyanosis (15%) or paleness, increased perspiration, fever (38.5%), dyspnoea (with 
acute onset 80%), tachpnea (70%), hemoptysis (11%), mortal fear, syncope (19%), low blood 
pressure, haemodynamic failure with large vessel obstruction, arrhythmia (atrial or 
ventricular extrasystole, acute atrial fibrillation, flutter, etc.) (Miniati, Prediletto, Formichi, 
Marini, Di Ricco, Tonelli, Allescia & Pistolesi, 1999a; Stein & Henry, 1997). 
1.4.2 Chest X-ray 
According to the PISAPED study, occlusion of the hilar artery, oligaemia, wedge shaped 
infiltration against the pleural wall is detectable in 15-45% of all cases (Miniati, Prediletto, 
Formichi, Marini, Di Ricco, Tonelli, Allescia & Pistolesi, 1999b). In acute PE the typical X-ray 
signs can be weak or absent, but a single-sided elevation of the diaphragm, stripe-like 
atelectasis and the oedema of the affected pulmonary tissue (Westermark-sign) may develop 
with the prominence of the pulmonary artery. Occasionally unilateral pleural effusion is 
present. Chest X-ray is useful to exclude certain diagnoses. 
1.4.3 Electrocardiography (ECG) 
The most common alterations are: sinus tachycardia, S1Q3T3 waveform (McGinn-White 
syndrome), acute P-pulmonale, negative T waves in V1-3 leads, incomplete or complete right 
bundle branch block, signs of RV strain, acute atrial fibrillation, atrio-ventricular conduction 
failures. Enlarged SISIISIII waveform develops after the dilatation of the right cavities causing 
the rotation of the cardiac axis. ECG signs are positive only in 50% of all patients (Torbicki et 
al., 2000; Torbicki et al., 2008; Geibel et al., 2005; Rodger, Makropoulos, et al., 2000). 
1.4.4. Perfusion scintigraphy 
Multiple studies have confirmed the benefit of perfusion scintigraphy as a non-invasive 
diagnostic procedure. It is necessary to combine perfusion scintigraphy with additional 
radiology imaging, like ventilation scintigraphy or chest X-ray. Various studies have 
confirmed that ventilation-perfusion scintigraphy has a positive predictive value of 88% 
(The PIOPED Investigators, 1990; Lee et al., 2005). The PISAPED study divided the 
probability of PE into 3 groups based on chest X-ray and perfusion scintigraphy results 
(Miniati et al., 1996). The sensitivity of perfusion scintigraphy is 92% with a positive 
predictive value of 92%. It has a negative predictive value of 88% with the specificity of 87%. 
Chronic pulmonary diseases caused perfusion defects may produce PE characteristic false 
results. To sum up, scintigraphy can help to exclude PE (error rate: 0.9%, confidence 
interval: 2.3%) (Kruip et al., 2003).  
1.4.5 Angiography 
According to the most recent PE guideline, the use of angiography is questionable as an 
invasive and hazardous intervention with mortality rate of 0.2%. The use of angiography is 
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recommended in case of uncertain radiological imaging results. Non-invasive CT 
angiography offers comparable or better sensitivity (Wan et al., 2004; Agnelli et al., 2002).  
1.4.6 Computed tomography, multidetector computed tomography (MDCT) 
The MDCT is a non-invasive approach, replacing angiography without the need of central 
venous access. It has a sensitivity of 83% and specificity of 96%. The negative predictive 
value of MDCT for PE is 89% in the intermediate and 96% in the low clinical risk groups. 
The cost-benefit and cost-life ratio increases significantly with the combination of MDCT 
and D-dimer assessment (Perrier et al., 2004; van Belle et al., 2006). With MDCT imaging one 
can visualise pulmonary vasculature up to the segmental level. An MDCT result showing a 
PE up to the segmental level could be taken as firm evidence (Eyer et al., 2005; Brunot et al., 
2005; Righini et al., 2008; Ghaye et al., 2001; Perrier et al., 2004).  
 
 
 
 
Fig. 1. Computed tomography image of acute pulmonary embolism.  
(From authors own collection. A: aorta, TP: pulmonary trunk, F: thoracic effusion, Thr: clot) 
1.4.7 Echocardiography 
Transthoracic echocardiography 
Echocardiography is a useful bedside non-invasive procedure in the differential diagnosis of 
various conditions (acute myocardial infarction, aortic dissection, pericardial tamponade, 
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chest pain, valve dysfunction, hypovolaemia). The sensitivity of echocardiography is about 
60-70% in PE. Negative results do not exclude PE. Acute massive PE has characteristic 
echocardiography signs: RV hypokinesis and/or dilatation, the end diastolic diameter of the 
RV in the parasternal short axis > 30 mm, or RV/LV end diastolic diameter ratio > 0.9, in the 
apical or subcostal axis, D-sign, increased pulmonary arterial pressure, dilatation of the 
inferior caval vein. A heart cavity thrombus, patent foramen ovale (with the risk of paradox 
thrombi), tricuspidal valve thrombosis or vegetation and floating clot in the right ventricle 
can also be visualised.  
The positive echocardiographic result has a predictive value in haemodynamically stable 
patient, as the intermediate risk group has worse outcome (Konstantinides, 2008; Torbicki et 
al., 2003; Ferrari et al., 2005; Hsiao et al., 2006; Casazza et al., 2005; Bova et al., 2003; Miniati 
et al., 2001; Roy et al., 2005; Konstantinides et al., 1998). 
Transoesophageal echocardiography 
The transoesophageal echocardiography is a semi-invasive diagnostic procedure, which can 
be useful in mechanically ventilated patients. Benefits of the transoesophageal approach are: 
visualisation of thrombi in the pulmonary trunk and/or main pulmonary arteries and also 
in the caval vein. Possible tumours originating from the heart or floating into the cavities of 
the heart can also be visualised (Sanchez et al., 2008). 
1.4.8 The diagnosis of DVT 
With duplex ultrasound the clot is visible as a hyperechogenic signal. The procedure has 95-
98% specificity. The sensitivity for PE is rather low, only 30-50% of PE cases present DVT 
with ultrasonography (Lee et al., 2005). The only validated verification method is the 
incomplete compressibility of the vein indicating the presence of the clot (Goldhaber & 
Morrison, 2002; Lee et al., 2005; Le Gal et al., 2006). 
Although extremity CT can also aid the diagnosis of DVT, the increased irradiation, need of 
contrast agent and elevated costs contraindicate the use of CT scan in all cases (Brenner & 
Hall, 2007). 
1.4.9 Laboratory diagnostics 
Arterial blood gas analysis: Hypocapnia with hypoxaemia is characteristic for PE. About 20% 
of patients have a normal arterial oxygen tension and normal alveolar-arterial oxygen 
gradient (Rodger, Carrier, et al., 2000; Stein et al., 1996).  
D-dimer is a fibrin degradation product. Quantitative ELISA or ELISA-like methods are 99% 
sensitive, if D-dimer concentration is above 500 µg/l. According to Dunn et al. the 
sensitivity for PE is 96.4%, with a negative predictive value of 99.6%, specificity 52.0% and 
positive predictive value 9.5%. Although the measurement is specific for fibrin, but the 
specificity of fibrin for VTE is considerably lower, the summarized specificity is only 40-
65%. The D-dimer test can be positive in the following diseases: infections, tumours, 
necrosis, pregnancy, postnatal, postoperative state, sepsis, etc., therefore, it cannot be used 
generally. In emergency situations, the D-dimer test is useful to exclude PE from differential 
diagnosis. Segal recommended the inclusion of D-dimer into the Geneva and Wells score 
systems (Dunn et al., 2002; Segal, Eng, et al., 2007; Spannagl et al., 2005; Reber et al., 2004; 
van Belle et al., 2006). 
Cardiac troponin T and B-type natriuretic peptide (BNP): Increased cardiac troponin and BNP 
levels are good indicators of impaired RV function. About 11-50% of PE patients show 
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increased marker levels. Echocardiography results correlate showing a decreased RV 
function. Negative troponin results are good predictors of favourable outcome. Both 
markers are useful and independent predictors of the 30 days mortality. Impaired RV 
function with increased troponin and BNP are relative indications of thrombolysis (TL) 
therapy in the intermediate risk group (Giannitsis et al., 2000; Kostrubiec et al., 2005; Krüger 
et al., 2004; ten Wolde et al., 2004; Worth, 2009). The recommended therapeutic approach 
according to Kucher and Goldhaber based on these data (Kucher & Goldhaber, 2003):  
 
without shock shock
BNP ↓and
Troponin↓
BNP ↑and
Troponin ↑
Echocardiography
without RV dysfunction RV dysfunction
Anticoagulant treatment Immediate thrombolysis or embolectomy
 
Fig. 2. Kucher and Goldhaber recommendation for the treatment of pulmonary embolism 
based on biomarkers and echocardiography. 
Cases with severe haemodynamic shock present elevated lactate and metabolic acidosis due 
to global microcirculatory impairment and tissue hypoxaemia. These markers can predict 
poor outcome. 
According to the recent guidelines, the diagnosis of PE is mainly based on the results of 
echocardiography, MDCT and biomarkers (Torbicki et al., 2008). 
1.5 Therapy 
1.5.1 Acute therapy 
For main therapeutic recommendations, we follow the ESC 2008 guidelines (Torbicki et al., 
2008). Anticoagulation therapy should be initiated upon suspicion of PE. 5000 IU Na-heparin 
is recommended as intravenous bolus if the patient had not already received Low Molecular 
Weight Heparin (LMWH) previously. Besides providing secure venous access, patients should 
receive immediate oxygen therapy through a 50% or 100% face mask. The indication of oxygen 
therapy is absolute, but mechanical ventilation should be used with caution. Mechanical 
ventilation may decrease the venous reflow and increases RV insufficiency, therefore,  
low tidal volume (7 ml/kg) ventilation and intravenous fluid therapy is recommended.  
The alveolar-arterial gas exchange can also be impaired as shunt-flow and cardiac  
output decrease (Singer, M; Webb, 2004; Sevransky et al., 2004). Capnometry is highly  
recommended during mechanical ventilation, as it may change due to thrombolysis  
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Fig. 3. The ESC 2008 guideline recommended diagnostic steps for high risk PE patients 
 
Non-high risk PE (without Shock or hypotension)
High probability of
PE
Low probability of
PE
Multidetector CT
D-dimer
Multidetector CT
positivenegative
negative positive
No PE
treatment
PE
treatment
No PE
treatment, look
for other cause
PE
treatment
No PE
treatment
Look for clinical PE signs!
positivenegative
 
Fig. 4. The ESC 2008 guideline recommended diagnostic steps for non-high risk PE patients 
or re-embolism. Morphine (or other opiate analgesic) can be administered as repeated 
intravenous bolus of 2 mg for analgesia. To achieve optimal haemorheological parameters 
and a desirable volume state, aggressive fluid resuscitation must be carried out 
intravenously in the acute phase (crystalloid 1.5-2 ml/kg/h). Early fluid resuscitation is 
recommended based on hypotension from the loss of LV end diastolic volume. Ozier et al. 
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measured the effect of 600 ml crystalloid infusion and found an increase of cardiac index 
from 1.7 to 2.0 l/min/m2. Also, Mercat et al. found the same increase of cardiac index after 
the infusion of 500 ml dextrane. Modest fluid challenge is recommended, as fluid overload 
may depress contractility and decrease cardiac output (Kasper et al., 1997; Mercat et al., 
1999; Ozier et al., 1984). If bronchospasm develops 200 mg intravenous theophyllin may be 
administered. If required, norepinephrine and/or dobutamine are the choice of positive 
inotropic drugs. Norepinephrine improve RV function with direct effect on contractility 
(Prewitt, 1990). Büchner primary recommends norepinephrine and dobutamine 
combination for haemodynamic shock (S. Büchner & Th. Hachenberg, 2005). 
Elevated lactate levels indicate capillary perfusion impairment. The normalisation of lactate 
shows the resolution of the haemodynamic failure. Also, a radial arterial line is useful for 
continuous blood pressure monitoring and to draw frequent blood samples upon the 
verification of high-risk or non high-risk PE. Pulse contour cardiac output systems, like the 
“PiCCO”-system (Pulsion Medical Inc., Germany) is capable of continuous haemodynamic 
monitoring including cardiac output. Phosphodiesterase-III inhibitors (i.e. enoximon) and 
Ca-channel sensitizers (i.e. levosimendan) may have a beneficial effect, but insufficient 
clinical evidence is available yet (Nowak et al., 2007; Kerbaul et al., 2007). Also, the 
inhalation of nitrous oxide may improve the gas exchange of patients with PE (Torbicki et 
al., 2008).  
If deep vein Doppler ultrasound suspects a floating, weak structure clot, thus re-
embolisation may occur, a temporary placement of caval vein filter should be considered 
before TL.  
 
Signs and symptoms of PE 
(blood gas, ECG etc.)
D-dimer, troponin, BNP
negative
No embolism, 
look for other 
cause
positive
MDCT 
if not available: 
echocardiography or perfusion 
scan + chest X-ray
positive + 
shock 
positive + stable
negative
positive  
(intermediate risk)
DVT US
Heparin/LMWH
TLcaval filter?
negative
negative
positive
positive
echocardiography
 
Fig. 5. The authors’ own diagnostic and therapeutic approach (US: ultrasound) 
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1.5.2 Thrombolysis 
Based on this complex classification a planned approach is essential. The aim of the 
management of acute severe PE is the resolution of the pulmonary artery obstruction. The 
most common procedure is TL, but invasive radiology procedures (clot fragmentation and 
vacuum evacuation, or selective TL through catheter arteriography, Class IIb C) or acute 
surgical embolectomy (Class I C) can also remove PE. 
In critical patients with severe shock and confirmed PE the indication of urgent systemic TL 
is absolute (Class I A). The recommended medications and appropriate dosage is available 
in the current PE guideline (Table 3). The authors support the accelerated TL (rt-PA or SK) 
protocol in haemodynamically instable patients. According to our experience the ultra-high 
dose streptokinase is an economically reasonable and effective alternative to rt-PA (Sárosi et 
al., 1997; Sárosi et al., 1995). 
 
Medication Continuous TL Accelerated TL 
streptokinase (SK) 250,000 IU/30 min, following 
100,000 IU/h for 12-24 hours 
1.5 IU/2 hours 
urokinase (UK) 4,400 IU/kg/10 min, following 
4,400 IU/kg/h for 12-24 hours 
3 IU/2 hours 
 
rt-PA 100 mg/2 hours 
 
0.6 mg/kg/15 min 
(max: 50 mg) 
Table 3. Recommended thrombolytic regimens (Torbicki et al., 2008) 
In the intermediate-risk group, with main arterial embolism and increased RV load, positive 
D-sign, elevated troponin and BNP levels but without haemodynamical impairment, TL is 
recommended only after considering relative contraindications and acquisition of written 
informed consent (Class IIb B).  
Certain patient history absolutely contraindicates TL: haemorrhagic stroke, or stroke of 
unconfirmed origin, ischemic stroke in the last 6 months, central nervous system tumour, 
neuro, trauma, or general surgery intervention in the last 3 weeks, gastrointestinal bleeding 
in the last 30 days, known bleeding, or bleeding disorder. 
The relative contraindications are: transient ischemic attack in the last 6 months, oral 
anticoagulation (vitamin K antagonists), pregnancy and the 1st week following labour, 
organ biopsy and non-compressible puncture, traumatic resuscitation, critical 
hypertension (RRs > 180 mmHg), advanced liver disease, infective endocarditis, active 
peptic ulcer (Torbicki et al., 2008). In life-threatening situations, every contraindication 
can be considered to be relative.  
The effectiveness of TL should be controlled between 12 and 24 hours by a second look 
MDCT or other available diagnostic procedure (perfusion lung scan or echocardiography). If 
the decrease of unperfused area does not improve by 30% following the first treatment 
cycle, TL should be repeated after 24 hours.  
During resuscitation, chest compressions assist the mechanical fragmentation of clot and 
improve the infiltration of drugs into the clot. Urokinase 2-3 MIU, rt-PA 2 × 50 mg or 
streptokinase 1.5 MIU (may repeat once after 15 minutes) can be used for TL. Compressions 
should continue for at least 90 minutes during TL. As TL is beneficial in PE and also in acute 
myocardial infarction, no firm diagnostic evidence is needed for the treatment (Böttiger & 
Spöhr, 2003). One main advantage of TL is the possibility of prompt use and that it may 
improve overall microcirculation (Böttiger & Martin, 2001). 
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Based on our previous clinical investigations, in case of bleeding complications the 
repetitive measurement of clot formation factors (namely fibrinogen and plasminogen) may 
indicate the need of specific factor replacement or fresh frozen plasma infusion during or 
following TL. Major bleeding complications can be reduced below 5%, if factor replacement 
takes place in patients with fibrinogen levels below 1.5 g/l accompanied by minor bleeding 
disorder or fibrinogen levels < 0.6 g/l (Mühl et al., 2007). 
Patients may not benefit from the TL of a more than 5-7 days old clot. Also, a second 
unsuccessful TL may indicate the presence of an older, connective tissue rich clot. Invasive 
radiology clot fragmentation and removal with or without selective TL should be used in 
these scenarios.  
Anticoagulation therapy during TL: In the rt-PA group unfractionated heparin is 
recommended during TL (500-1000 IU/h, based on actual partial thromboplastin time 
(aPTT) levels on admission) (Segal, Streiff, et al., 2007). 
Anticoagulation therapy after TL: Anticoagulant therapy starts after strepto- or urokinase TL 
with intravenous unfractionated heparin to maintain aPTT (check every 4 hours!) between 
50-70 seconds for the first 48 hours and continues with a therapeutic dose of LMWH, if no 
further TL cycle is necessary. Using the “Heparin adjustment nomogram”, the dose of Na-
heparin is adjusted to reach a target aPTT (Torbicki et al., 2008). 
Anticoagulant therapy should be provided with intravenous unfractionated heparin to 
maintain the aPTT between 60-70 seconds for 48 hours. If TL was effective it should be 
continued with a therapeutic dose of LMWH. Following TL, long term anticoagulation 
(acenocoumarol or warfarin) can start on day 3 or 4 (Torbicki et al., 2008; Kearon et al., 2008).  
In case of unfractioned heparin use, the incidence of HIT is 1-3% (about 1% with LMWH), 
therefore regular platelet count check is recommended (Greinacher, 2009; Morris et al., 
2007). In case of confirmed HIT, one should switch from heparin/LMWH therapy to: 
hirudin, lepirudin, danaparoid or fondaparinux. 
One of the most common complication of TL is minor bleeding (arterial/venous port 
bleeding, haematuria, suffusions, e.t.c.), major bleeding occurs in 13% of cases. The 
incidence of intracranial haemorrhage is 1.8% (Spöhr et al., 2005), (Konstantinides et al., 
2002; Goldhaber et al., 1993). 
1.5.3 Catheter extraction and surgical embolectomy 
Indications of percutaneous catheter embolectomy and fragmentation are unsuccessful 
systemic TL, contraindicatons of systemic lysis, PE with haemodynamic shock 
(resuscitation, mechanical ventilation), clot in the right heart, and also an alternative for the 
surgical embolectomy if no experienced team is available (Kucher et al., 2005; Uflacker, 
2001). 
Surgical embolectomy has a high mortality rate in the high-risk PE group. Indications are 
narrow, only patients with absolute systemic TL contraindications and in the absence of 
consent for TL may benefit from surgical intervention (Meneveau et al., 2006). Previous 
unsuccessful TL is not a contraindication for surgical embolectomy (Aklog et al., 2002). 
1.5.4 Intravenous (caval) filter 
Statistically there is no firm evidence of improved 12 days mortality of the caval filter use. 
Transient caval filters may be used up to 14 days. Late complications include migration and 
device thrombosis. Indications are not general; the main indication is suspected 
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reoccurrence of PE and contraindication of long-term anticoagulation (Hann & Streiff, 2005). 
Also, venous filters for PE prophylaxis may be beneficial in trauma patients, but further 
studies are required to draw firm clinical evidence (Rajasekhar et al., 2011). 
1.5.5 Follow-up after PE therapy 
Following PE therapy, a switch from heparin/LMWH to oral anticoagulation is 
recommended. Oral anticoagulation should be continued for 6 months. Following, an 
extended diagnostic procedure should take place to elucidate possible genetic factors or 
acquired thrombophylia behind the development of PE. In case of irreversible 
complications or positive thrombotic predisposition, continuous oral anticoagulation is 
needed (Kearon et al., 2008).  
2. A new approach to PE 
2.1 The role of matrix metalloproteinases  
Experimental evidence indicated that the pathophysiology of PE implies the activation of 
matrix metalloproteinases (MMPs) (Uzuelli et al., 2008; Dias-Junior et al., 2009; Souza-Costa 
et al., 2005; Souza-Costa et al., 2007; Palei et al., 2005; Fortuna et al., 2007). Indeed, 
hemodynamic derangements associated with this condition improved with the inhibition of 
MMPs. Neutrophil activation (Eagleton et al., 2002) and rapid release of granules 
containing large amounts of MMP-9 in inflammation (Van den Steen et al., 2002) and 
during PE explains how MMPs, especially MMP-9, are involved in pathophysiology of 
PE. The increased activity and levels of MMP-9 found in ischemic stroke, or the 
upregulation of the enzyme after cerebral ischemia are interestingly similar to PE (Asahi 
et al., 2000). The degradation of type IV collagen, laminin, and fibronectin by MMP-9, may 
contribute to hemorrhagic transformation after cardioembolic stroke as these components 
are the main structure of the vascular matrix (Rosell et al., 2008; Montaner et al., 2001). 
Also, tissue plasminogen activator (or alteplase) can amplify MMP-9 levels by 
upregulation, thus increasing ischemic brain damage (Wang et al., 2004; Burggraf et al., 
2007; Ning et al., 2006; Tsuji et al., 2005). There is evidence, that increased plasmin 
concentration may activate MMPs. Previous experimental work by our group aimed to 
assess the levels of MMPs following fibrinolysis for acute PE. Circulating levels of MMPs 
were measured serially (MMP-9 and MMP-2). Their endogenous inhibitors, tissue 
inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 were also measured in alteplase and 
in ultra-high dose streptokinase-treated patients with acute PE (Mühl et al., 2010). 
2.2 Measurements and discussion of TIMP/MMP changes in PE 
In our study MMP levels were assessed by sodium-dodecil-sulphate polyacrylamide gel 
electrophoresis, TIMP levels were measured with a commercially available ELISA kit (Mühl 
et al., 2010). Significant increases in pro-MMP-9 concentrations were found after TL therapy 
in both groups, but these were not associated with significant alterations in TIMP-1 levels. 
Pro-MMP-9/TIMP-1 ratio increased significantly. Interestingly, earlier increases in pro-
MMP-9 levels and in pro-MMP-9/TIMP-1 ratio were found in subjects treated with 
streptokinase. From the 3rd day pro-MMP-9 levels and pro-MMP-9/TIMP-1 ratio returned to 
normal. No significant changes in pro-MMP-2 concentrations were measured after TL. 
Moreover, we found no significant changes in TIMP-2 concentrations or in pro-MMP-
2/TIMP-2 ratio.  
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Although there is a lack of firm evidence, the possible explanation for increased MMP-9 
levels during treatment with alteplase is the promotion of MMP-9 release by neutrophils 
(Cuadrado et al., 2008). According to our knowledge, no previous study has reported that 
streptokinase induces the release of MMP-9. 
A slower increase of pro-MMP-9 was found in alteplase treated patients, but the precise 
explanation for this difference between fibrinolytic agents is not yet elucidated. There is 
significant interindividual variability in neutrophil degranulation (Cuadrado et al., 2008), 
therefore a multi-central study may draw firm evidence on this question.  
No definitive conclusion can be drawn yet, but it is widely acknowledged that intracerebral 
hemorrhage is the most feared bleeding complication of TL (Arcasoy & Kreit, 1999). The use 
of alteplase enhanced MMP-9 levels, which has already been widely associated with 
hemorrhagic transformation after cardioembolic stroke (Rosell et al., 2008; Montaner et al., 
2001). This observation offers an explanation for the hemorrhagic transformation during 
stroke.  
It is possible that the MMP inhibitors may decrease the risk of intracerebral hemorrhage or 
other bleeding complication of TL for acute PE (Murata et al., 2008; Sumii & Lo, 2002; 
Machado et al., 2009) and may have beneficial hemodynamic effects (Fortuna et al., 2007; 
Palei et al., 2005).  
3. Summary 
Following risk stratification, prompt and specific diagnostics are life-saving in acute PE. 
Recommended diagnostic tools are biomarkers, MDCT and electrocardiography. Systemic 
TL is the first choice for high-risk PE patients, in case of contraindications surgical 
embolectomy or catheter clot fragmentation/removal should be considered. The fast 
resolution of haemodynamic shock indicates accelerated protocol systemic TL (rt-PA, SK or 
UK), as continuous TL dissolve clot slower and have a higher risk of bleeding disorder. The 
regular control of fibrinogen and plasminogen during and after TL, and clot formation 
factor supplement can reduce bleeding complications. 
There is emerging evidence of the hypothesized role of the TIMP/MMP system in the 
development of bleeding complication. In future, pharmacological approach to MMP 
inhibition in human medicine may decrease the incidence of bleeding complications of TL.  
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